Aarhus University Hospital in Skejby, Jutland, has developed a genetic test which can reveal at an early stage how an individual patient will develop bladder cancer, thereby guiding doctors towards the appropriate treatment. An international study has demonstrated that the genetic test is effective, and the hospital has just received DKK 25 m (USD 4.7 m) in funding from the EU Commission for a new and larger study involving 2,000 patients from four European countries.
Professor Torben Ørntoft at the Molecular Diagnostic Laboratory, Aarhus University Hospital, Skejby, is heading the project, which is being conducted in collaboration with cancer research centres in Spain, Holland and Sweden.
The EU funding will be used to study the course of the disease in 2,000 patients and compare it to the genetic activity in tumours, blood and urine. The aim is to identify the most reliable genetic characteristics of various types of bladder cancer tumour, and to develop a computer programme which can predict the course of the disease for each patient. The programme can be used by doctors to help them decide on the right treatment.
Each year, approx. 1,500 Danes are diagnosed with bladder cancer, 75% of whom are men, making it the fifth most common form of cancer among men. The news was reported by professional journal Ingeniøren (The Engineer).